Alamar Biosciences Expands Neurodegenerative Disease Panel with 220-Biomarker NULISAseq™ Platform
Event summary
- Alamar Biosciences launched the NULISAseq™ Neuro 220 Panel on March 17, 2026, expanding its precision proteomics capabilities for neurological disease research.
- The panel includes 15 new Parkinson’s biomarkers developed with support from The Michael J. Fox Foundation and 12 assays specific to brain and peripheral Tau isoforms.
- The NULISAseq Neuro 220 Panel will be featured at the AD/PD 2026 conference in Copenhagen, Denmark, with over 11 scientific sessions and 25 posters showcasing its utility.
The big picture
Alamar Biosciences' launch of the NULISAseq Neuro 220 Panel underscores the growing emphasis on precision proteomics in neurological disease research. The panel's expanded biomarker coverage, particularly for Alzheimer’s and Parkinson’s diseases, positions Alamar as a key player in advancing early detection and therapeutic development. The strategic partnership with The Michael J. Fox Foundation further strengthens its standing in the neurodegenerative disease research community.
What we're watching
- Market Adoption
- How quickly the NULISAseq Neuro 220 Panel will be adopted by research institutions and pharmaceutical companies for neurodegenerative disease studies.
- Competitive Positioning
- Whether Alamar Biosciences can maintain its leadership in precision proteomics amid growing competition in the biomarker development space.
- Regulatory Approvals
- The pace at which regulatory approvals for diagnostic and therapeutic applications of the NULISAseq platform will be achieved.
Related topics